ETTX: Entasis Therapeutics Holdings Inc. - Summary | Jitta

Entasis Therapeutics Holdings Inc.

NASDAQ:ETTX

Notice
Stock data is unavailable or the company’s delisted.
Price
n/a
Loss Chance
58.4%
0.01JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (0)
Recent Business Performance (0)
Financial Strength (0)
Return to Shareholders (10)
Competitive Advantage (0)
Jitta Signs
Recent IPOLess than 3 years
Key Stats
Jitta Score
Jitta Line
0.01
100.00%
2.22
137.59%
COMPANY DESCRIPTION
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing ETX2514SUL, a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, an oral antibiotic monotherapy that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and various antibiotics for gram-negative infections. The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Drugs for Neglected Diseases initiative. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts.